Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s Why

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $4.84, but opened at $4.63. Inventiva shares last traded at $4.65, with a volume of 161,983 shares changing hands.

Analyst Ratings Changes

IVA has been the subject of a number of research analyst reports. Cantor Fitzgerald began coverage on shares of Inventiva in a research report on Friday, July 17th. They set an “overweight” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.38.

Inventiva Stock Performance

The business’s 50 day simple moving average is $4.48 and its 200 day simple moving average is $5.03.

Institutional Investors Weigh In On Inventiva

A number of large investors have recently bought and sold shares of IVA. Paradigm Biocapital Advisors LP bought a new position in Inventiva in the 4th quarter valued at $18,600,000. ADAR1 Capital Management LLC bought a new stake in shares of Inventiva during the fourth quarter worth $12,601,000. UBS Group AG increased its stake in shares of Inventiva by 28,881.6% in the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after buying an additional 2,634,580 shares in the last quarter. SymBiosis Capital Partners LLC acquired a new stake in shares of Inventiva in the fourth quarter valued at $12,090,000. Finally, Millennium Management LLC raised its holdings in shares of Inventiva by 2,267.7% in the fourth quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after buying an additional 2,540,540 shares during the last quarter. 19.06% of the stock is currently owned by institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.